The ameliorative effects of thymoquinone and beta-aminoisobutyric acid on streptozotocin-induced diabetic cardiomyopathy

FM Gur, I Aktas - Tissue and Cell, 2021 - Elsevier
Diabetic cardiomyopathy (DCM) is a cardiac dysfunction observed in a patient with diabetes
that may lead to heart failure. No specific treatment has yet been tested in DCM. Therefore …
被引用次数：16 相关文章
[PDF] researchgate.net

[PDF][PDF] The ameliorative effects of thymoquinone and beta-aminoisobutyric acid on streptozotocin-induced diabetic cardiomyopathy

FM Gur, I Aktas - researchgate.net
Diabetic cardiomyopathy (DCM) is a cardiac dysfunction observed in a patient with diabetes
that may lead to heart failure. No specific treatment has yet been tested in DCM. Therefore …

The ameliorative effects of thymoquinone and beta-aminoisobutyric acid on streptozotocin-induced diabetic cardiomyopathy

FM Gur, I Aktas - Tissue & cell, 2021 - pubmed.ncbi.nlm.nih.gov
Diabetic cardiomyopathy (DCM) is a cardiac dysfunction observed in a patient with diabetes
that may lead to heart failure. No specific treatment has yet been tested in DCM. Therefore …

The ameliorative effects of thymoquinone and beta-aminoisobutyric acid on streptozotocin-induced diabetic cardiomyopathy.

FM Gur, I Aktas - Tissue & Cell, 2021 - europepmc.org
Diabetic cardiomyopathy (DCM) is a cardiac dysfunction observed in a patient with diabetes
that may lead to heart failure. No specific treatment has yet been tested in DCM. Therefore …

The ameliorative effects of thymoquinone and beta-aminoisobutyric acid on streptozotocin-induced diabetic cardiomyopathy.

FM Gur, I Aktas - 2021 - cabidigitallibrary.org
Diabetic cardiomyopathy (DCM) is a cardiac dysfunction observed in a patient with diabetes
that may lead to heart failure. No specific treatment has yet been tested in DCM. Therefore …